Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vidarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.97 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.97 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.97 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.97 |
| ▸ | DPP4 | P27487 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.97 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.97 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.97 |
| ▸ | GAPDH | P04406 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | STAT6 | P42226 | 1/20 | 0.97 |
| ▸ | PI4KA | P42356 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.97 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.97 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.97 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.97 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vidarabine SCHEMBL30994790 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL15741481 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL4993136 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL14719528 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL1046366 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL5078118 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL5500833 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4280020 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL10764695 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL27624165 | 1.00 | ADORA3 (0.97) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 30533 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4746876-A1 | UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE SYNTHASE (UGCG) INHIBITORS IN THE TREATMENT OF CANCER | Katholieke Universiteit Leuven (BE) | 2026-05-27 | — | — | EP | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| US-12630593-B2 | Method of killing leukemia cells by administration of recombinant'Y3 proteins | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-19 | — | — | US | claimed |
| EP-4729525-A1 | NEWLY SYNTHESIZED BORON-NITROGEN HETEROCYCLES AND THEIR CONJUGATES WITH PHARMACEUTICALLY UTILIZABLE SUBSTANCES | Julius-Maximilians-Universität Würzburg (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-12595280-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2026-04-07 | — | — | US | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | claimed |
| EP-0162747-A1 | Lysine esters used as absorption enhancing agents | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| EP-0153371-A1 | ANTI-VIRAL COMPOSITIONS | BLANTON, George (US) | 1985-09-04 | — | — | EP | claimed |
| US-4537772-A | Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines | MERCK & CO., INC. (US) | 1985-08-27 | — | — | US | claimed |
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | claimed |
| EP-0135312-A2 | Anti-viral compositions | SCOTIA PHARMACEUTICALS LIMITED (GB) | 1985-03-27 | — | — | EP | claimed |
| WO-1985000815-A1 | ANTI-VIRAL COMPOSITIONS | BLANTON GEORGE | 1985-02-28 | — | — | WO | claimed |
| EP-0042596-B1 | NOVEL ADENINE NUCLEOSIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1984-03-14 | — | — | EP | claimed |
| US-4385112-A | CULTURES, PSEUDOMONAS, QUANTITATIVE NUCLEOSIDE ASSAY, MAKING NUCLEOSIDE-5-CARBOXYLIC ACIDS | TOYO JOZO KABUSHIKI KAISHA (JP) | 1983-05-24 | — | — | US | claimed |
| EP-0042596-A1 | Novel adenine nucleoside derivatives, their preparation and pharmaceutical compositions containing them | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1981-12-30 | — | — | EP | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |